Rein Therapeutics, Inc. announced preliminary blinded data from its ongoing Phase 2 RENEW clinical trial evaluating its lead drug candidate, LTI-03, in patients with idiopathic pulmonary fibrosis (IPF). The company also reported financial results for the third quarter ended September 30, 2026.

The preliminary analysis included 24 patients with evaluable baseline and Week 12 forced vital capacity (FVC) measurements. The data indicates that 33% of patients demonstrated an improvement in FVC from baseline at Week 12. The range of change in FVC at Week 12 ranged from an improvement of 338 ml to a decline of 349 ml. The company noted that 46% of patients experienced an FVC decline of no more than 5.7%, a threshold associated with a greater than 2X likelihood of progression to lung transplant or death in some studies.

Regarding safety, the report states that preliminary blinded safety observations suggest a favorable profile. No serious adverse events related to the study treatment have been reported as of the interim data cutoff. Adverse events were predominantly mild or moderate, with cough being the most frequently reported. The discontinuation rate was low, with 92% of enrolled participants remaining on or completing the study.

As of November 2026, the trial has achieved 75% of its planned enrollment, with 90 patients randomized to date across the United States, United Kingdom, Australia, Germany, and Poland. Rein Therapeutics remains on track to report topline data in 2027.

Financially, as of September 30, 2026, the company reported cash, cash equivalents, and marketable securities totaling $36.5 million. The company stated that this cash position is expected to fund operations into the first quarter of 2028 through the completion of the Phase 2 RENEW clinical trial.

Research and development expenses for the quarter ended September 30, 2026, were $4.4 million, compared to $1.7 million in the prior year period. This increase was primarily attributed to increased spending on the RENEW phase 2 clinical trial. General and administrative expenses were $2.6 million for the quarter, compared to $3.8 million in the prior year period. Net loss for the quarter was $5.5 million.